Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. University of Birmingham, Birmingham, United Kingdom

Survival: 24.5 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United Kingdom
City/State/Province: Birmingham
Hospital: University of Birmingham
Journal: Link
Date: 5/2009

Patients: This phase 2 study involved 312 men with metastatic hormone refractory prostate cancer. They ranged in age from 49 to 91 years old. Almost all (more than 90%) had previously been treated with hormone therapy.

Treatment: Patients were treated with one of two doses of ZD4054 or a placebo (a substance that looks like the study drug but does not have any activity). ZD4054 is a biological therapy (an endothelin-A receptor antagonist). It works by blocking or inhibiting the action of a receptor on certain cells.

Toxicity: The most common toxicities (grade 1 and 2) were peripheral edema, headache, nasal congestion, back pain, nausea, allergic rhinitis, and fatigue. Grade 3 and 4 toxicities were reported in less than 5% of patients and included peripheral edema, headache, nasal congestion, dyspnea (breathlessness), anemia, and cardiac (heart)-related problems.

Results: The median overall survival was 24.5 months for the group receiving the lower dose of ZD4054, 23.5 months for the higher dose, and 17.3 months for those receiving the placebo.

Support: This study was supported by funds from Astra Zeneca, which developed ZD4054.

Correspondence: Dr. Nicholas D. James.

E-mail to a Friend Email Physician More Information